PDCD1 and non-small cell lung carcinoma: We compared NSCLC patients receiving anti-PD-1 antibody treatment with and without antibiotics and found that both the PFS and overall survival (OS) were significantly lower in the group that used some antibiotics within 3 weeks before and after the start of anti-PD-1 antibody treatment than those in the group that did not use antibiotics.